Your browser doesn't support javascript.
loading
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
Huang, Richard S P; Carbone, David P; Li, Gerald; Schrock, Alexa; Graf, Ryon P; Zhang, Liangliang; Murugesan, Karthikeyan; Ross, Jeffrey S; Tolba, Khaled; Sands, Jacob; Oxnard, Geoffrey R; Spigel, David.
Afiliación
  • Huang RSP; Foundation Medicine Inc, Cambridge, Massachusetts, USA rhuang@foundationmedicine.com.
  • Carbone DP; The Ohio State University and the Pelotonia Institute for Immune Oncology, Columbus, Ohio, USA.
  • Li G; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Schrock A; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Graf RP; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Zhang L; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Murugesan K; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Ross JS; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Tolba K; Upstate Medical University, Syracuse, New York, USA.
  • Sands J; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Oxnard GR; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Spigel D; Foundation Medicine Inc, Cambridge, Massachusetts, USA.
J Immunother Cancer ; 11(1)2023 01.
Article en En | MEDLINE | ID: mdl-36650021
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article